The optimal use of this marker in breast carcinomatosis is unclear, but its possible use in combination with other tumor markers, such as CA15-3 or CEA, is expected to be of complementary value for clinical decision making and to improve our understanding of the function of CA125 in human pathology. The gene discussed is CEACAM5; the disease is neoplasm.